as informed in bloomberg
Pfizer Beats Out Sanofi to Take Medivation for $14 Billion
Pfizer Beats Out Sanofi to Take Medivation for $14 Billion
Pfizer Inc. claimed the pharmaceutical industry's latest big prize Monday, beating out a group of rivals after months of jockeying to buy Medivation Inc. and its blockbuster cancer drug for $14 billion.Left behind was French drugmaker Sanofi, whose aggressive and at one point hostile pursuit of Medivation helped open up the process to Pfizer, Gilead Sciences Inc. and others that were said to be involved.Pfizer will pay $81.50 a share in cash, the companies said in a statement on Monday, well above Sanofi's initial $52.50 a share offer.By acquiring Medivation, Pfizer gets Xtandi, a cancer drug that's already approved for sale in the U.S. and elsewhere, and that analysts project will generate $1.33 billion in annual sales by 2020.
in the same way nytimes
Pfizer to Buy Medivation in $14 Billion Deal
Pfizer to Buy Medivation in $14 Billion Deal
Medivation, which makes treatments for prostate and breast cancers, has finally found its buyer in a fellow American drug maker, Pfizer.Pharmaceutical companies from all over the world placed bids for Medivation in an auction after it rebuffed an offer by the French drug maker Sanofi.On Monday, Pfizer said that it had prevailed, with a $14 billion agreement to acquire Medivation, representing about $81.50 a share in cash.The frenzy over Medivation shows what pharmaceutical companies are willing to pay for oncology deals.
let alone wsj
Pfizer to Buy Medivation for $14 Billion
Pfizer to Buy Medivation for $14 Billion
Pfizer Inc. said Monday that it had agreed to buy biotech Medivation Inc. for about $14 billion, in a move that adds one of the crown jewels of the multibillion-dollar market for cancer drugs to Pfizer's portfolio.News of the impending deal was reported Sunday.The deal ends months of bidding for San Francisco's Medivation, one of the...
not to mention businessinsider
Pfizer acquires Medivation for $14 billion
Pfizer acquires Medivation for $14 billion
Pfizer is scooping up the cancer drugmaker Medivation for $14 billion.The deal values Medivation at $81.50 a share, a notable premium to the $52.50-a-share offer Sanofi had made for it earlier this year.Medivation shares ended trading at $67.16 on Friday.Sanofi went public with its $9.3 billion bid for the company in April.
additionally thestreet
More Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion
More Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion
No comments:
Post a Comment